Molecular Templates, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Posters
  • Pipeline
    • Overview
    • MT-3724
    • MT-5111
    • TAK-169
  • Clinical Trials
    • Overview
    • MT-3724 With Lenalidomide for Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Active, not recruiting
    • MT-3724 for Relapsed or Refractory DLBCL Active, not recruiting
    • MT-3724 With Gemcitabine and Oxaliplatin for Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma Active, not recruiting
    • MT-5111 in HER2-positive Solid Tumors Recruiting
    • TAK-169 for Relapsed or Refractory Multiple Myeloma (RRMM) Recruiting
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
    • Email Alerts
  • Contact
  • Careers

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Email Alerts
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar

Molecular Templates, Inc. Reports Third Quarter 2019 Financial Results

Nov 12, 2019 5:00pm EST

Molecular Templates Hosting Analyst & Investor Meeting

Nov 07, 2019 4:27pm EST

Molecular Templates to Present at the Ladenburg Thalmann and Cantor Fitzgerald Healthcare Conferences

Sep 23, 2019 4:30pm EDT

Molecular Templates, Inc. Reports Second Quarter 2019 Financial Results

Aug 12, 2019 4:30pm EDT

Molecular Templates Announces FDA Acceptance of IND Application for TAK-169, An Engineered Toxin Body Targeting CD38

Jun 17, 2019 8:00am EDT

Molecular Templates to Present at the Oppenheimer New York Oncology Insight Summit and the UBS Global Healthcare Conference

May 14, 2019 4:30pm EDT

Molecular Templates, Inc. Reports First Quarter 2019 Financial Results

May 13, 2019 4:01pm EDT

Molecular Templates Announces FDA Acceptance of IND Application for MT-5111, An Engineered Toxin Body Targeting HER2

Apr 22, 2019 8:00am EDT

Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2019 Highlight Evolution of ETB Platform

Apr 02, 2019 7:00am EDT

Molecular Templates, Inc. Reports Fourth Quarter 2018 Financial Results

Mar 28, 2019 4:30pm EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2021 Molecular Templates, Inc. All Rights Reserved.
    Twitter Linkedin
    Privacy Policy Disclaimer Terms of Use Sitemap